Galderma Announces Departure of Its Chief Financial Officer#

Galderma Group AG (SIX), a leading dermatology company, announced on July 1, 2025, that Chief Financial Officer Thomas Dittrich will depart in Q2 2026 to pursue another senior executive opportunity outside the organization. Dittrich will remain in his role through the close of the 2025 fiscal year to ensure a smooth transition, with a successor to be announced later. Link

Leadership Contributions and Transition#

Thomas Dittrich’s Role: Dittrich played a pivotal role in establishing Galderma’s financial discipline, operational readiness, and strategic clarity, contributing to its transformation and growth. CEO Flemming Ørnskov praised his leadership, noting its lasting impact on the company’s trajectory.
Transition Plan: Dittrich’s extended tenure until Q2 2026 will facilitate a seamless handover, maintaining stability during the fiscal year-end. Galderma is actively seeking a new CFO to continue its growth momentum.
Dittrich’s Statement: Reflecting on his tenure, Dittrich described it as “the most impactful transformation and growth journey of my career,” expressing pride in Galderma’s achievements and confidence in its future.

Galderma’s Market Position#

Company Overview: Founded in 1981, Galderma operates in approximately 90 countries, offering a science-based portfolio across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its focus on skin health drives innovation and partnerships with healthcare professionals.
Recent Developments: Galderma reported an 8.3% sales increase to 1.13 billion in Q1 2025, maintaining its 2025 outlook despite U.S. tariff uncertainties. The company established a new U.S. headquarters in Miami in June 2025, appointing Heather Wallace as President of Galderma U.S. to bolster its largest market. Link Link
Market Performance: On July 1, 2025, Galderma’s stock (SIX) fell 2.66%, reflecting market reactions to the CFO departure and broader sector challenges, including a UBS downgrade citing headwinds in the aesthetics market.

Strategic Outlook#

Growth Strategy: Galderma remains committed to expanding market share through new product launches and its U.S. market focus, as emphasized by CEO Ørnskov’s commitment to growth despite external uncertainties. Link
Risks and Forward-Looking Statements: The announcement includes forward-looking statements about Galderma’s financial condition, growth, and strategies, which are subject to risks such as global economic conditions, market competition, and regulatory changes. Actual results may vary, and Galderma is not obligated to update these projections unless required by law.

Conclusion#

Thomas Dittrich’s departure as Galderma’s CFO marks the end of a transformative period for the company, which has strengthened its financial foundation and market position under his leadership. With a transition plan in place and a robust growth strategy, Galderma is poised to maintain its leadership in dermatology. Stakeholders should monitor the upcoming CFO appointment and Q2 2026 fiscal results for insights into the company’s trajectory. For further information, contact Galderma’s investor relations at www.galderma.com or certified financial advisors. Link